Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many people have been treated with Ronapreve for covid-19 (a) in each week and (b) in each clinical commissioning group area since that treatment became available; and how many of those recipients had blood cancer.

An interim clinical policy for Ronapreve (casirivimab and imdevimab) was published on 17 September 2021 and updated on 4 November. Since September 2021, over 1,200 patients in England have received this treatment.

NHS England and NHS Improvement collect information from trusts on usage based on the criteria set out in the policy for treatment of patients hospitalised due to COVID-19. The data collection is not designed to identify the number of such patients who have blood cancer. The information on the number of patients treated in each clinical commissioning group area and in each week is not currently available.